Jennison Associates LLC Aeglea Bio Therapeutics, Inc. Transaction History

Jennison Associates LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 10, 2019	SELL	$7.6 - $9.4 $4.38 Million - $5.41 Million	-575,696 Reduced 42.59%	776,094 $6.25 Million
Q4 2018 Feb 06, 2019	SELL	$6.51 - $10.19 $1.18 Million - $1.84 Million	-180,611 Reduced 11.79%	1,351,790 $10.1 Million
Q3 2018 Nov 08, 2018	BUY	$8.24 - $11.0 $57,300 - $76,494	6,954 Added 0.46%	1,532,401 $14.7 Million
Q2 2018 Aug 02, 2018	BUY	$7.87 - $10.89 $160,146 - $221,600	20,349 Added 1.35%	1,525,447 $16.1 Million
Q1 2018 Apr 20, 2018	BUY	$5.07 - $10.9 $566,111 - $1.22 Million	111,659 Added 8.01%	1,505,098 $14.9 Million
Q4 2017 Jan 25, 2018	BUY	$4.0 - $5.98 $33,488 - $50,064	8,372 Added 0.6%	1,393,439 $7.54 Million
Q3 2017 Nov 03, 2017	BUY	$2.91 - $4.93 $4.03 Million - $6.83 Million	1,385,067	1,385,067 $6.57 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.